Cathepsins and their role in gynecological cancers: Evidence from two-sample Mendelian randomization analysis DOI Creative Commons

Xiaoying Li,

Lingyi Sun, Xiaoting Wu

и другие.

Medicine, Год журнала: 2025, Номер 104(10), С. e41653 - e41653

Опубликована: Март 7, 2025

Prior studies have reported connections between cathepsins (CTS) and gynecological cancers; however, the exact causal links are yet to be fully understood. Leveraging publicly accessible genome-wide association study summary datasets, we performed a two-sample bidirectional Mendelian randomization (MR) multivariate MR (MVMR) analysis, with inverse variance weighted (IVW) method as primary approach. analysis demonstrated associations CTSB cervical cancer (IVW: odds ratio [OR] = 0.9995, 95% confidence interval [CI] 0.9991-0.9999, P .0418), CTSE ovarian OR 0.9197, CI 0.8505-0.9944, .0358), CTSZ 0.9449, 0.8938-0.9990, .0459), high grade serous 0.8939, 0.8248-0.9689, .0063), 0.9269, 0.8667-0.9913, .0268). A positive correlation was identified CTSH clear cell 1.1496, 1.0368-1.2745, .0081). Nevertheless, subsequent adjustment for false discovery rate revealed that none of P-values retained statistical significance (PFDR > 0.05). MVMR results elucidated inversely associated 0.9988, 0.9981-0.9996, .0022). Moreover, noted CTSF 1.0007, 1.0000-1.0014, .0364), similarly, CTSS 1.0005, 1.0000-1.0011, .0490). CTSO exhibited non-endometrioid endometrial 1.4405, 1.1864-1.7490, < .001), positively 1.1167, 1.0131-1.2310, .0263). The findings reveal emerges protective element against cancer, whereas represent risk factors this disease. stands out factor acts cancer. This elucidates causative CTS cancers, providing innovative insights diagnostic therapeutic optimization.

Язык: Английский

PCAB Safety: Balancing Potential Long‐Term Risks With Short‐Term Benefits DOI Open Access
Stephanie Y. Owyang, Wai–Kit Lo

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Янв. 16, 2025

Potassium-competitive acid blockers (PCABs), such as vonoprazan, provide more rapid, potent and prolonged suppression than proton pump inhibitors (PPIs), may offer advantages in the treatment of GERD other acid-related disorders. PPI-related adverse effects, including enteric infection, pneumonia, micronutrient deficiencies, have been attributed primarily to gastric [1], which raises concerns that treatment-emergent events (TEAEs) could be profound with PCAB use. The current study by Howden et al. [2] found vonoprazan is well-tolerated, a safety profile comparable PPIs. This based on an assessment TEAEs across 14 clinical trials compared lansoprazole, esomeprazole or placebo, addition post-marketing data from 2014–2023. While short-term seems supported, study's mean exposure duration 142 days (20 weeks/5 months) maximum 260 weeks (5 years) incomplete longer-term profile. Notably, several PPI-associated can only fully evaluated after chronic exposure, bone fracture, vitamin B12 deficiency malignancy. Bone fracture has associated PPI use at least 7 years, but not less 6 years [3]; thus, this analysis sufficient detect increased incidence fractures. mechanism due calcium magnesium malabsorption, occurs over 5–10 [4]. Additionally, while impact mineral density controversial, timing osteoporosis development women exceed 10 [5]. Vitamin take 3–5 deplete body, usually presenting no minimal symptoms short term additional decades manifest clinically glossitis, anaemia neuropsychiatric dysfunction [6], though association between dementia remains controversial [7]. Gastric malignancy often arises subacute process, median time progression 6.1 nondysplastic intestinal metaplasia adenocarcinoma [8]. Risk cancer cumulative dose well longer therapy (> 3 [9], was inconsistent studies involve various mechanisms, H. pylori infection alterations GI microbiota [10]. Of note, serious were identified potentially related investigators included acute cholangitis, diverticulitis, malignancies, thyroiditis, atrial fibrillation transient loss consciousness. Additional evaluation needed determine frequency, causality potential mechanisms action. Despite use, PPIs remain mainstay for numerous conditions because, ultimately, absolute risk low, debated, few therapeutic alternatives exist. there yet long-term draw same conclusions, we believe PCABs likely role conditions, particularly those failed, future evaluations real-world application will clarify harms benefits presently underappreciated. Stephanie Owyang: conceptualization, writing – original draft, review editing. Wai-Kit Lo: editing, supervision. article linked al paper. To view article, visit https://doi.org/10.1111/apt.18458. Data sharing applicable datasets generated analysed during study.

Язык: Английский

Процитировано

0

Immediate and delayed hypersensitivity reactions to Proton pump inhibitors: A review article DOI Creative Commons

Vahida Ćorović,

Irfan Ćorović,

Vahid Ademović

и другие.

SANAMED, Год журнала: 2025, Номер 00, С. 80 - 80

Опубликована: Янв. 1, 2025

Proton pump inhibitors (PPIs) are among the most widely prescribed medications in clinical practice, primarily used for managing acid-related gastrointestinal disorders. While generally regarded as safe, with adverse effects being rare and typically mild, PPIs have been associated hypersensitivity reactions. These reactions, which may be immediate or delayed, vary severity from mild to potentially life-threatening. This review provides an in-depth analysis of key aspects PPI use, a particular emphasis on pathophysiological characteristics both delayed It also explores cross-reactivity offers practical framework assist clinicians diagnosing these conditions effectively. Additionally, highlights critical need further research develop standardized diagnostic therapeutic protocols, enabling personalized evidence-based care patients experiencing PPI-related hypersensitivity.

Язык: Английский

Процитировано

0

Cathepsins and their role in gynecological cancers: Evidence from two-sample Mendelian randomization analysis DOI Creative Commons

Xiaoying Li,

Lingyi Sun, Xiaoting Wu

и другие.

Medicine, Год журнала: 2025, Номер 104(10), С. e41653 - e41653

Опубликована: Март 7, 2025

Prior studies have reported connections between cathepsins (CTS) and gynecological cancers; however, the exact causal links are yet to be fully understood. Leveraging publicly accessible genome-wide association study summary datasets, we performed a two-sample bidirectional Mendelian randomization (MR) multivariate MR (MVMR) analysis, with inverse variance weighted (IVW) method as primary approach. analysis demonstrated associations CTSB cervical cancer (IVW: odds ratio [OR] = 0.9995, 95% confidence interval [CI] 0.9991-0.9999, P .0418), CTSE ovarian OR 0.9197, CI 0.8505-0.9944, .0358), CTSZ 0.9449, 0.8938-0.9990, .0459), high grade serous 0.8939, 0.8248-0.9689, .0063), 0.9269, 0.8667-0.9913, .0268). A positive correlation was identified CTSH clear cell 1.1496, 1.0368-1.2745, .0081). Nevertheless, subsequent adjustment for false discovery rate revealed that none of P-values retained statistical significance (PFDR > 0.05). MVMR results elucidated inversely associated 0.9988, 0.9981-0.9996, .0022). Moreover, noted CTSF 1.0007, 1.0000-1.0014, .0364), similarly, CTSS 1.0005, 1.0000-1.0011, .0490). CTSO exhibited non-endometrioid endometrial 1.4405, 1.1864-1.7490, < .001), positively 1.1167, 1.0131-1.2310, .0263). The findings reveal emerges protective element against cancer, whereas represent risk factors this disease. stands out factor acts cancer. This elucidates causative CTS cancers, providing innovative insights diagnostic therapeutic optimization.

Язык: Английский

Процитировано

0